Myelodysplastic Syndromes

Drugs for Myelodysplastic Syndromes

Find financial assistance programs available for myelodysplastic syndrome drugs.

Gleevec (imatinib mesylate) Tablets

Drug company: Novartis

Gleevec is a kinase inhibitor used for the treatment of patients with myelodysplastic syndromes or myeloproliferative disease associated with PDGFR gene rearrangements, as determined by an FDA-approved test.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Gleevec:

Novartis Oncology Universal Co-pay Program

Eligible patients with private insurance may pay only $10 for a 30-day supply of Gleevec, with a maximum benefit of $10,630 per 30-day supply up to an annual maximum benefit of $30,000.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Gleevec for free through the Novartis Patient Assistance Foundation. To be eligible for financial assistance, the patient must be a US citizen and must provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Gleevec for free until prescription drug coverage becomes available to them.

Inqovi (decitabine + cedazuridine) Tablets

Drug company: Taiho Oncology

Inqovi is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor, used for treatment of adults with myelodysplastic syndromes (MDS), including previously treated and untreated MDS with refractory types of anemia, and chronic myelomonocytic leukemia, and intermediate-risk or high-risk MDS.

Taiho Oncology offers 2 financial assistance programs for patients who have been prescribed Inqovi:

Taiho Oncology Patient Support Co-pay Assistance Program

Eligible patients who have commercial (or private) insurance may have a $0 copay per treatment cycle of Inqovi, for a maximum benefit limit of $6,000 per month and $36,000 per year.

Patient Assistance Program

This program offers financial assistance for eligible patients who are uninsured or underinsured and who have insufficient financial resources to pay for Inqovi. Patients may receive Inqovi for free based on assistance, financial, and medical criteria.

Revlimid (lenalidomide) Capsules

Drug company: Bristol Myers Squibb

Revlimid is a thalidomide analog used for the treatment of transfusion-dependent anemia caused by low- or intermediate-risk myelodysplastic syndromes that is associated with a deletion 5q cytogenetic abnormality, with or without additional cytogenetic abnormalities.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Revlimid:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductible, copay, or co-insurance costs for eligible patients with private insurance who have been prescribed Revlimid. Patients pay a $10 copay, while BMS covers the remaining amount, up to $15,000 annually.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Revlimid, may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.

Table. Drugs Prescribed for Myelodysplastic Syndromes

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services

Share this:

Last modified: April 1, 2022

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice

Receive timely cancer news & updates, patient stories, and more.

Race or Ethnicity
Profession or Role
Primary Interest
Other Interests